Infusion Reactions clinical trials

Explore recruiting infusion reactions clinical trials.

Recruiting infusion reactions studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Infusion Reactions trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (EMERALD)

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Impact of early proactive therapeutic drug monitoring on the durability and efficacy of infliximab therapy in pediatric inflammatory bowel disease: a multicenter open-label randomized-control trial

Italy

Therapeutic use (Phase IV) EU CTIS Study details

A randomized Phase 2, open-label study of mirvetuximab soravtansine in patients with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression testing 2 schedules of administration for dose optimization, with a separate cohort to determine starting dose in patients with moderate hepatic impairment

Belgium, Poland, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

CD8 PET imaging in metastatic solid tumours; A phase II, open label, multi-center study of 89Zr-DF-crefmirlimab for CD8 positron emission tomography in patients with locally advanced or metastatic solid tumors

Netherlands, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)

Greece, Czechia, Portugal

Therapeutic exploratory (Phase II) EU CTIS Study details

Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS)

Norway, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Infusion Reactions trials by city

Infusion Reactions in Toronto Infusion Reactions in Vancouver Infusion Reactions in Montreal Infusion Reactions in Calgary Infusion Reactions in Edmonton Infusion Reactions in Ottawa Infusion Reactions in Winnipeg Infusion Reactions in Quebec City Infusion Reactions in Hamilton Infusion Reactions in Kitchener Infusion Reactions in London Infusion Reactions in Halifax Infusion Reactions in New York Infusion Reactions in Los Angeles Infusion Reactions in Chicago Infusion Reactions in Houston